Evens Andrew M, Hutchings Martin, Diehl Volker
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.
Nat Clin Pract Oncol. 2008 Sep;5(9):543-56. doi: 10.1038/ncponc1186.
Significant advances in the biology and treatment of Hodgkin lymphoma (HL) have been accomplished over the past decades. In a landmark study, DeVita and colleagues showed that half of patients with advanced-stage HL experienced long-term disease-free survival following treatment with a four-drug chemotherapy regimen. Subsequent reports and randomized clinical trials conducted over the past 40 years have defined prognostic categories and refined the treatment options for patients with early-stage and advanced-stage HL. New treatment concepts and regimens have continued to increase the cure rate of HL, while other analyses have documented the acute and long-term morbid and potentially fatal side effects of HL therapy. Increased knowledge of HL biology has been gained, in particular, much has been learnt about the genetic and phenotypic characteristics of malignant cells and the varied oncogenic signaling pathways involved in HL. Continued translational research is needed to improve the long-term survival and to lessen the toxicities associated with therapy. Furthermore, continued clinical-trial involvement by oncologists and patients is imperative to further advance the field of HL.
在过去几十年里，霍奇金淋巴瘤（HL）的生物学研究和治疗取得了重大进展。在一项具有里程碑意义的研究中，德维塔及其同事表明，一半的晚期HL患者在接受四药化疗方案治疗后实现了长期无病生存。随后在过去40年里进行的报告和随机临床试验确定了预后类别，并完善了早期和晚期HL患者的治疗选择。新的治疗理念和方案不断提高HL的治愈率，而其他分析记录了HL治疗的急性和长期病态及潜在致命副作用。人们对HL生物学的认识有所增加，特别是对恶性细胞的遗传和表型特征以及HL中涉及的各种致癌信号通路有了更多了解。需要持续的转化研究来提高长期生存率并减轻与治疗相关的毒性。此外，肿瘤学家和患者持续参与临床试验对于进一步推动HL领域的发展至关重要。
